Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 11/20 | 0.49 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.42 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.42 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.42 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.42 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.42 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL926489 | 0.97 | FKBP1A (0.52) | FKBP1APSEN1PSEN2APH1BNCSTN | |
| SCHEMBL926338 | 0.94 | FKBP1A (0.49) | FKBP1APSEN1PSEN2APH1BNCSTN | |
| SCHEMBL927527 | 0.91 | FKBP1A (0.48) | FKBP1APSEN1PSEN2APH1BNCSTN | |
| SCHEMBL926406 | 0.88 | FKBP1A (0.47) | FKBP1APSEN1PSEN2APH1BNCSTN | |
| SCHEMBL926836 | 0.88 | FKBP1A (0.48) | FKBP1ARORCALDH1A1MAPTMEN1 | |
| SCHEMBL927595 | 0.87 | POLB (0.51) | FKBP1AMAPK1ALDH1A1MEN1KMT2A | |
| SCHEMBL926912 | 0.87 | FKBP1A (0.54) | FKBP1APSEN1PSEN2APH1BNCSTN | |
| SCHEMBL926686 | 0.87 | ESRRG (0.47) | FKBP1APSEN1PSEN2APH1BNCSTN | |
| SCHEMBL928733 | 0.86 | PSEN1 (0.51) | FKBP1APSEN1PSEN2APH1BNCSTN | |
| SCHEMBL929397 | 0.86 | ESRRG (0.47) | FKBP1APSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872021-B2 | LXR receptor modulators | LABORATORIES FOURNIER S.A. (FR) | 2011-01-18 | — | — | US | disclosed |
| US-20070099960-A1 | LXR receptor modulators | LABORATOIRES FOURNIER S.A. (FR) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099960-A1 | LXR receptor modulators | NR1H2, NR1H3, PPARD | FKBP1A 2748/4885PSEN1 281/4885PSEN2 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.